Link to paper: www.nejm.org/doi/full/10....
Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD | NEJM
Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...
www.nejm.org
October 20, 2025 at 6:22 PM
Link to paper: www.nejm.org/doi/full/10....
If you gave a tool calling LLM the ability to send an email and it uses true knowledge it has to extort you I think you’d consider that a threat. This is a totally practical risk give how these models are getting deployed now.
October 14, 2025 at 2:14 AM
If you gave a tool calling LLM the ability to send an email and it uses true knowledge it has to extort you I think you’d consider that a threat. This is a totally practical risk give how these models are getting deployed now.
at least only speaking for myself, my goal is still the culture
February 8, 2025 at 7:27 PM
at least only speaking for myself, my goal is still the culture
the books don’t form a single narrative, they’re all different stories set in the same overall universe. By the “first book” I assume you mean Consider Phlebas; you might find Player of Games better, or maybe Surface Detail or Excession. All very different stories.
November 29, 2024 at 5:24 AM
the books don’t form a single narrative, they’re all different stories set in the same overall universe. By the “first book” I assume you mean Consider Phlebas; you might find Player of Games better, or maybe Surface Detail or Excession. All very different stories.
i've been noticing this too with the firefox extension! i increasingly have to download the pdf separately and add it to the record.
November 28, 2024 at 5:44 PM
i've been noticing this too with the firefox extension! i increasingly have to download the pdf separately and add it to the record.
Next stop, applying for the CE mark so we can make it available to patients in Europe (where the trial was done).
November 26, 2024 at 3:05 PM
Next stop, applying for the CE mark so we can make it available to patients in Europe (where the trial was done).